AU2004212842B9 - Method for treating severe heart failure and medicament therefor - Google Patents

Method for treating severe heart failure and medicament therefor Download PDF

Info

Publication number
AU2004212842B9
AU2004212842B9 AU2004212842A AU2004212842A AU2004212842B9 AU 2004212842 B9 AU2004212842 B9 AU 2004212842B9 AU 2004212842 A AU2004212842 A AU 2004212842A AU 2004212842 A AU2004212842 A AU 2004212842A AU 2004212842 B9 AU2004212842 B9 AU 2004212842B9
Authority
AU
Australia
Prior art keywords
heart failure
pharmaceutically acceptable
acceptable salt
medicament
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004212842A
Other languages
English (en)
Other versions
AU2004212842A1 (en
AU2004212842B2 (en
Inventor
Yosuke Maki
Atsushi Ozaki
Osamu Sato
Yoshitaka Yamamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004212842(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2004212842A1 publication Critical patent/AU2004212842A1/en
Publication of AU2004212842B2 publication Critical patent/AU2004212842B2/en
Application granted granted Critical
Publication of AU2004212842B9 publication Critical patent/AU2004212842B9/en
Priority to AU2009201109A priority Critical patent/AU2009201109A1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004212842A 2003-02-24 2004-02-23 Method for treating severe heart failure and medicament therefor Expired AU2004212842B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009201109A AU2009201109A1 (en) 2003-02-24 2009-03-19 Method for treating severe heart failure and medicament therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24
US60/448,878 2003-02-24
PCT/JP2004/002085 WO2004073716A1 (en) 2003-02-24 2004-02-23 Method for treating severe heart failure and medicament therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009201109A Division AU2009201109A1 (en) 2003-02-24 2009-03-19 Method for treating severe heart failure and medicament therefor

Publications (3)

Publication Number Publication Date
AU2004212842A1 AU2004212842A1 (en) 2004-09-02
AU2004212842B2 AU2004212842B2 (en) 2009-01-08
AU2004212842B9 true AU2004212842B9 (en) 2009-03-05

Family

ID=32908667

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004212842A Expired AU2004212842B9 (en) 2003-02-24 2004-02-23 Method for treating severe heart failure and medicament therefor
AU2009201109A Abandoned AU2009201109A1 (en) 2003-02-24 2009-03-19 Method for treating severe heart failure and medicament therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009201109A Abandoned AU2009201109A1 (en) 2003-02-24 2009-03-19 Method for treating severe heart failure and medicament therefor

Country Status (23)

Country Link
US (2) US7423032B2 (enExample)
EP (2) EP1596868B1 (enExample)
JP (2) JP4771937B2 (enExample)
KR (1) KR100706727B1 (enExample)
CN (1) CN100577171C (enExample)
AR (1) AR043259A1 (enExample)
AT (1) ATE411803T1 (enExample)
AU (2) AU2004212842B9 (enExample)
BR (1) BRPI0405657A (enExample)
CA (1) CA2493475A1 (enExample)
CY (1) CY1108583T1 (enExample)
DE (1) DE602004017283D1 (enExample)
DK (1) DK1596868T3 (enExample)
ES (1) ES2315640T3 (enExample)
MX (1) MXPA05001623A (enExample)
MY (1) MY143740A (enExample)
NO (1) NO335369B1 (enExample)
PL (2) PL218069B1 (enExample)
PT (1) PT1596868E (enExample)
RU (2) RU2346689C2 (enExample)
SI (1) SI1596868T1 (enExample)
TW (1) TWI322689B (enExample)
WO (1) WO2004073716A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
AU2006330277B2 (en) 2005-12-27 2011-10-06 Otsuka Pharmaceutical Co., Ltd. Water-soluble benzoazepine compound and its pharmaceutical composition
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
UA99914C2 (ru) * 2007-05-15 2012-10-25 Оцука Фармас'Ютікел Ко., Лтд. Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
ES2903231T3 (es) 2008-02-26 2022-03-31 Jenavalve Tech Inc Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
WO2015028209A1 (en) 2013-08-30 2015-03-05 Jenavalve Technology Gmbh Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
WO2016150806A1 (en) 2015-03-20 2016-09-29 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath
EP3288495B1 (en) 2015-05-01 2019-09-25 JenaValve Technology, Inc. Device with reduced pacemaker rate in heart valve replacement
JP7081749B2 (ja) 2016-05-13 2022-06-07 イエナバルブ テクノロジー インク 心臓弁プロテーゼ送達システム
WO2018138658A1 (en) 2017-01-27 2018-08-02 Jenavalve Technology, Inc. Heart valve mimicry
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用
WO2024102411A1 (en) 2022-11-09 2024-05-16 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01102124A (ja) 1987-10-14 1989-04-19 Kubota Ltd コンクリート構造体支持構造
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
WO1991005549A1 (en) 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
TW249201B (enExample) 1992-07-02 1995-06-11 Otsuka Pharma Co Ltd
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
AU2001218083A1 (en) 2000-01-26 2001-08-07 Warner Lambert Company Ace inhibitor-vasopressin antagonist combinations
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) * 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
ES2288899T3 (es) * 2000-10-04 2008-02-01 Astellas Pharma Inc. Uso de un antagonista de vasopresina tal como conivaptan en la fabricacion de un medicamento para el tratamiento de la hipertension pulmonar.
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Burrell et al, Am J of Physiology, 1998, vol 275, no 1, 00 H176-H182. *
Martinez-Castelao, Current Opinions in Cardiovascular, Pulmonary & Renal Investigational Drugs, 1999, vol 1, no 3, pp 423-432. *
Naitoh et al, Am J of Physiology, 1994, vol 267, no 6, pp H2245 -H2254. *
Nishikimi et al, J of Cardiovasular Pharmacology, 1996, vol 27, no 2, pp 275-282. *
Shimizu et al, Naika Hokan, 1993, vol 40, no 1, pp 7-11. *
Sorbera et al, Drugs of the future, 2002, vol 27, no 4, p350-357 *

Also Published As

Publication number Publication date
AR043259A1 (es) 2005-07-20
CN1700919A (zh) 2005-11-23
KR20050105972A (ko) 2005-11-08
RU2005102110A (ru) 2005-09-20
PT1596868E (pt) 2009-01-14
TWI322689B (en) 2010-04-01
NO20050569D0 (no) 2005-02-02
SI1596868T1 (sl) 2008-12-31
NO20050569L (no) 2005-11-22
JP2011148806A (ja) 2011-08-04
US20050187210A1 (en) 2005-08-25
CY1108583T1 (el) 2014-04-09
EP1596868A1 (en) 2005-11-23
PL404315A1 (pl) 2013-08-05
ATE411803T1 (de) 2008-11-15
JP2006518731A (ja) 2006-08-17
WO2004073716A1 (en) 2004-09-02
RU2346689C2 (ru) 2009-02-20
TW200418489A (en) 2004-10-01
MY143740A (en) 2011-07-15
CN100577171C (zh) 2010-01-06
ES2315640T3 (es) 2009-04-01
EP1596868B1 (en) 2008-10-22
US7423032B2 (en) 2008-09-09
BRPI0405657A (pt) 2005-07-19
AU2004212842A1 (en) 2004-09-02
EP2000142A1 (en) 2008-12-10
PL218069B1 (pl) 2014-10-31
US7749993B2 (en) 2010-07-06
MXPA05001623A (es) 2005-04-25
RU2008133654A (ru) 2010-02-20
US20080214523A1 (en) 2008-09-04
HK1084037A1 (zh) 2006-07-21
NO335369B1 (no) 2014-12-01
DK1596868T3 (da) 2008-12-08
AU2004212842B2 (en) 2009-01-08
PL373432A1 (en) 2005-08-22
DE602004017283D1 (de) 2008-12-04
EP1596868A4 (en) 2006-03-29
JP4771937B2 (ja) 2011-09-14
KR100706727B1 (ko) 2007-04-12
AU2009201109A1 (en) 2009-04-09
CA2493475A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
US7749993B2 (en) Method for treating severe heart failure and medicament therefor
EP2059245A1 (en) Bifeprunox doses for treating schizophrenia
EP2706997B1 (en) Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
EP2853261B1 (en) Agent for improving vesicourethral dyssynergia
EP4360631A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
CA2375751A1 (en) Use of cortisol antagonists in the treatment for heat failure
EP3332779A1 (en) Ameliorating agent for detrusor hyperactivity with impaired contractility
CN101507726A (zh) 窦房结If电流抑制剂和β-阻滞剂的组合
CA3218550A1 (en) Dosing regimens
HK1084037B (en) Medicament for treating severe heart failure
MX2013013124A (es) Combinaciones de trospio y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
JP3002766B2 (ja) 脳浮腫治療剤
HK40044975A (en) Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia
CN112512526A (zh) 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
CN101573117A (zh) 用于治疗精神分裂症的联苯芦诺剂量
Munger et al. Invasive pharmacodynamic characterization of combined ibopamine and calcium blocker therapy for heart failure
HK1133190A (en) Bifeprunox doses for treating schizophrenia
JPH06211657A (ja) 尿酸排泄剤
HK1078012A (en) Therapeutic agent for overactive bladder

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired